2012
The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer
Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, McKenna M, Wu X, Hildebrandt M, Zelterman D, Sand S, Shulman LP. The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer. PLOS ONE 2012, 7: e37891. PMID: 22662244, PMCID: PMC3360659, DOI: 10.1371/journal.pone.0037891.Peer-Reviewed Original ResearchConceptsPrimary patientsOvarian cancer riskKRAS-variantOvarian cancer diagnosisOvarian cancerPrimary cancerFamily historyCancer diagnosisCancer riskTriple-negative breast cancerAdditional cancer diagnosesDouble primary breastTriple primary cancersPositive family historyAge of diagnosisNegative breast cancerDeleterious BRCA mutationsBreast primaryPathologic diagnosisBRCA mutationsPrimary breastBreast cancerHBOC familiesPatientsHereditary breast
2003
Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary.
Tangir J, Zelterman D, Ma W, Schwartz P. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstetrics And Gynecology 2003, 101: 251-7. PMID: 12576247, DOI: 10.1016/s0029-7844(02)02508-5.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBiopsy, NeedleChemotherapy, AdjuvantCohort StudiesCombined Modality TherapyFemaleFertilityFollow-Up StudiesGerminomaHumansInfertility, FemaleLogistic ModelsMiddle AgedMinimally Invasive Surgical ProceduresNeoplasm StagingOvarian NeoplasmsOvariectomyPregnancyProbabilityRetrospective StudiesRisk AssessmentSurvival RateTreatment OutcomeConceptsMalignant germ cell tumorsGerm cell tumorsFertility-preserving surgeryCell tumorsFollow-upReproductive functionInternational Federation of Gynecology and Obstetrics (FIGO) stage ITreated with other combinationsStage IIIStage IFIGO stage IFertility-preserving treatmentMedian follow-upLoss of follow-upActinomycin DCase series analysisReproductive function of womenFollow-up informationConservative surgeryNo chemotherapyCongenital anomaliesFunction of womenChemotherapyTumorCisplatin
2001
The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.
Peng X, Won J, Rutherford T, Fujii T, Zelterman D, Pizzorno G, Sapi E, Leavitt J, Kacinski B, Crystal R, Schwartz P, Deisseroth A. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. Cancer Research 2001, 61: 4405-13. PMID: 11389068.Peer-Reviewed Original ResearchMeSH KeywordsAdenoviridaeAnimalsCytomegalovirusCytosine DeaminaseFemaleFlucytosineFluorouracilGene ExpressionGenetic TherapyGenetic VectorsHumansInhibitory Concentration 50Lac OperonMembrane GlycoproteinsMiceMice, NudeMicrofilament ProteinsNucleoside DeaminasesOvarian NeoplasmsPhosphoproteinsPromoter Regions, GeneticTumor Cells, CulturedUrinary Bladder NeoplasmsXenograft Model Antitumor AssaysConceptsL-plastin promoterBladder cancer cell linesNormal ovarian cellsCancer cell linesOvarian cancer cellsTumor nodulesAdenoviral vectorCell linesNormal peritoneal mesothelial cellsOvarian cellsCD vectorSKOV-3 ovarian cancer cell lineFibroblast cell lineReplication-incompetent adenoviral vectorCancer cellsOvarian cancer cell linesNormal peritoneal cellsPeritoneal mesothelial cellsMouse xenograft modelCytosine deaminase geneSurgical specimensOvarian cancerTumor-specific gene expressionPeritoneal cellsOVCAR-5